GE HEALTHCARE TECHNOLOGY
GEHCNASDAQTrading Snapshot
- Day Range
- $74.64 β $77.88
- 52-Week Range
- $58.75 β $89.77
- Volume (shares)
- 9,566,604
- Avg Volume (shares)
- β
- Shares Outstanding
- 451.7M
- Next Earnings
- 2026-10-28
Fundamentals Snapshot
- Annual Revenue
- $20.63B
- Last Q Revenue
- $5.29B
- P/E Ratio
- 16.2
- P/S Ratio
- 1.5x
- EPS (TTM)
- $4.35
- Dividend Yield
- 0.20%
- Dilution (1yr)
- +0.3%
GE HEALTHCARE TECHNOLOGY
GEHCAbout GE HEALTHCARE TECHNOLOGY
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals β molecular tracers labeled with radioisotopes β injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Latest News & Updates

GE HealthCare Technologies Q3 Earnings Call Highlights
GE HealthCare Technologies NASDAQ: GEHC reported third-quarter 2026 revenue growth across all of its business segments, supported by demand in imaging and pharmaceutical diagnostics, improved execution in patient care pr

GE HealthCare Lifts Forecasts on Healthy Hospital Spending
GE HealthCare Technologies Inc. (NASDAQ:GEHC) shares rose Wednesday after the company reported third-quarter results that topped Wall Street estimates.

GE HealthCare Technologies Inc. (GEHC) Q3 2026 Earnings Call Transcript
GE HealthCare Technologies Inc. (GEHC) Q3 2026 Earnings Call Transcript

GEHC Q3 Earnings Beat Estimates on Strong Growth, '26 View Raised
GE HealthCare's Q3 earnings and revenues beat estimates on strong segment growth and higher margins, driving raised 2026 guidance as shares gain 8.3%.

Compared to Estimates, GE HealthCare (GEHC) Q3 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for GE HealthCare (GEHC) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Str

GE HealthCare Technologies (GEHC) Q3 Earnings and Revenues Beat Estimates
GE HealthCare Technologies (GEHC) came out with quarterly earnings of $1.34 per share, beating the Zacks Consensus Estimate of $1.21 per share. This compares to earnings of $1.07 per share a year ago.